RTW Biotech Opportunities Ltd Monthly Valuation Update, December Factsheet (5941Z)

TIDMRTW

RNS Number : 5941Z

RTW Biotech Opportunities Ltd

15 January 2024

LEI: 549300Q7EXQQH6KF7Z84

15 January 2024

RTW Biotech Opportunities Ltd

Monthly Valuation Update, December Factsheet

+15.0% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31st December 2023 (the "NAV") was US$399.3 million, or US$1.90 per ordinary share, +15.0% from the previous month.

The monthly factsheet is available on the Company's website:

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

Developments in the quarter:

-- NAV per share returned +19.1% versus +24.0% for the Russell 2000 Biotech Index and +10.5% for the Nasdaq Biotech Index (NBI).

-- On 1(st) November, the Company announced that the boards of RTW Bio and Arix Bioscience had agreed to the terms of a recommended all-share acquisition of Arix's assets by RTW Bio, to be affected through a scheme of reconstruction and the voluntary winding-up of Arix. The scheme will enhance RTW Bio's position as a leading UK-listed life sciences fund by adding significant scale.

-- The Federal Reserve's interest rate pivot and a flurry of takeouts helped the biotech sector avert an historic three down years in a row with a sharp rally in the last two months of the year.

-- Flows have been consistently negative all year, with total outflows the highest in three decades. Generalists have remained on the sidelines, but should the pivot hold, could return to the space.

-- The list of investible biotech assets has declined significantly in the past year with the acquisitions of Seagen, Horizon, Karuna, Prometheus, Immunogen, Cerevel, Reata, Televant, Iveric, Mirati, and Rayze having totalled over $150bn. which amounts to about a third of acquirable US market cap in the post-mega merger FTC era. Investors will compete with large pharma companies for the sector's remaining marquee assets.

-- In total, the FDA approved 61 novel drugs, the highest in history. Drugs from new modalities represented 14, one more than last year. We continue to expect more new highs to be set in the coming years.

-- Rocket Pharmaceuticals, Immunocore and Cargo Therapeutics were the largest contributors in the quarter. Rocket and Immunocore were largely driven by market moves with only small company specific updates. Cargo successfully debuted on Nasdaq in November raising $281m. The shares subsequently rallied from an offering price of $15 to finish the year at $23.15.

-- Milestone Pharmaceuticals was the only material detractor in the quarter, having received a refusal letter from the FDA to file for a New Drug Application for Etripamil for the treatment of PSVT. The FDA did not express concerns about the nature or severity of adverse events. Milestone will seek clarification and is in the process of planning a meeting with the FDA.

For Further Information:

 
 RTW Investments, LP                                        +44 20 7959 6361 
 Woody Stileman, Managing Director, Business Development 
  Krisha McCune, Director, Investor Relations 
 
 Buchanan                                                   +44 20 7466 5107 
 Charles Ryland 
 Henry Wilson 
 George Beale 
 
 Numis                                                      +44 20 7260 1000 
 Freddie Barnfield 
 Nathan Brown 
 Euan Brown 
 
 BofA Securities                                            +44 20 7628 1000 
 Edward Peel 
 Kieran Millar 
 
   Cadarn Capital                                             +44 73 6888 3211 
 David Harris 
 
   Elysium Fund Management Limited 
   Joanna Duquemin Nicolle, Chief Executive Officer 
   Sadie Morrison, Managing Director                          +44 (0) 14 8181 0100 
 Morgan Stanley Fund Services USA LLC                       +1 914 225 8885

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

   Visit the website at  www.rtwfunds.com/rtw-biotech-opportunities-ltd   for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCBTMFTMTIBBMI

(END) Dow Jones Newswires

January 15, 2024 02:00 ET (07:00 GMT)

Rtw Biotech Opportunities (LSE:RTWG)
過去株価チャート
から 11 2024 まで 12 2024